Synergistic Activity of Cefiderocol in Combination with Avibactam, Sulbactam or Tazobactam against Carbapenem-Resistant Gram-Negative Bacteria
Cells · 06.08.2024 · 13 (16) · 1315
DOI: 10.3390/cells13161315 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 06.08.2024. Verfasst von Russell E Lewis und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine, University of Padova, 35122 Padova, Italy. Hauptthemen laut MEDLINE: Azabicyclo Compounds, Tazobactam, Sulbactam, Drug Synergism. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FUR2024.
Abstract (Originalsprache)
We investigated the activity of cefiderocol/β-lactamase inhibitor combinations against clinical strains with different susceptibility profiles to cefiderocol to explore the potentiality of antibiotic combinations as a strategy to contain the major public health problem of multidrug-resistant (MDR) pathogens. Specifically, we evaluated the synergistic activity of cefiderocol with avibactam, sulbactam, or tazobactam on three of the most “Critical Priority” group of MDR bacteria (carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii). Clinical isolates were genomically characterized by Illumina iSeq 100. The synergy test was conducted with time-kill curve assays. Specifically, cefiderocol/avibactam, /sulbactam, or /tazobactam combinations were analyzed. Synergism was assigned if bacterial grow reduction reached 2 log10 CFU/mL. We reported the high antimicrobial activity of the cefiderocol/sulbactam combination against carbapenem-resistant Enterobacterales, P. aeruginosa, and A. baumannii; of the cefiderocol/avibactam combination against carbapenem-resistant Enterobacterales; and of the cefiderocol/tazobactam combination against carbapenem-resistant Enterobacterales and P. aeruginosa. Our results demonstrate that all β-lactamase inhibitors (BLIs) tested are able to enhance cefiderocol antimicrobial activity, also against cefiderocol-resistant isolates. The cefiderocol/sulbactam combination emerges as the most promising combination, proving to highly enhance cefiderocol activity in all the analyzed carbapenem-resistant Gram-negative isolates, whereas the Cefiderocol/tazobactam combination resulted in being active only against carbapenem-resistant Enterobacterales and P. aeruginosa, and cefiderocol/avibactam was only active against carbapenem-resistant Enterobacterales.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Medicine, University of Padova, 35122 Padova, Italy.
- IRCCS Azienda Ospedaliero, Universitaria di Bologna, 40135 Bologna, Italy.
- Department of Diagnostic and Public Health, Microbiology Section, Verona University, 37134 Verona, Italy.
ORCID-Profile: Erica Diani, Paolo Gaibani
Förderung
- FUR2024
Zitieren
APA
Lewis, R. E., Palombo, M., Diani, E., Secci, B., Gibellini, D., & Gaibani, P. (2024). Synergistic Activity of Cefiderocol in Combination with Avibactam, Sulbactam or Tazobactam against Carbapenem-Resistant Gram-Negative Bacteria. Cells, 13(16), 1315. https://doi.org/10.3390/cells13161315
Vancouver
Lewis RE, Palombo M, Diani E, Secci B, Gibellini D, Gaibani P. Synergistic Activity of Cefiderocol in Combination with Avibactam, Sulbactam or Tazobactam against Carbapenem-Resistant Gram-Negative Bacteria. Cells. 2024;13(16):1315. doi:10.3390/cells13161315
BibTeX
@article{Lewis2024,
author = {Lewis, Russell E and Palombo, Marta and Diani, Erica and Secci, Benedetta and Gibellini, Davide and Gaibani, Paolo},
title = {Synergistic Activity of Cefiderocol in Combination with Avibactam, Sulbactam or Tazobactam against Carbapenem-Resistant Gram-Negative Bacteria},
journal = {Cells},
year = {2024},
volume = {13},
number = {16},
pages = {1315},
doi = {10.3390/cells13161315}
}
EUVIMED